London, UK, 3rd October 2016 / Sciad Newswire / ReViral Ltd, a biotechnology company, aiming to help patients infected with respiratory syncytial virus (RSV) by developing novel compounds, is pleased to announce the appointment of Eddy Littler as CEO. Eddy joins ReViral from Domainex, a UK-based drug discovery company, where as CEO he successfully delivered major growth in size, revenues, and profit during his nine years in charge. Eddy also managed the pre-clinical development of the Domainex drug pipeline.
Over his distinguished career, Eddy has held senior positions in research and management in the pharmaceutical & biotech industries as well as in academia. He played a leading role in the development of several marketed drugs for herpes viruses, influenza, and viral hepatitis. While leading the antiviral team at Medivir, he played a principal role in out-licensing Simeprevir, a treatment for hepatitis C to J&J. Dr. Littler holds a Ph.D. from the University of Leeds, UK and is an expert in virology and drug-discovery.
“We are delighted that Eddy Littler is joining ReViral as Chief Executive Officer,” commented Ken Powell, Chairman of ReViral. “He is a tried and tested entrepreneurial business leader. His industry knowledge, track record and strong relationships are ideal skills to bring to ReViral. Eddy’s expertise in the antiviral area, leadership and experience are of significant benefit to the Company.”
Eddy Littler commented, “I am pleased to be joining ReViral as CEO at this critical time in its development where I can help move the Company’s lead programme RV521, forward into clinical development. The ground breaking projects and drug candidates at ReViral for treating RSV can translate into significant value for patients, clinicians, and ReViral shareholders and I look forward to contributing to the success of the Company.”
About ReViral
ReViral is an antiviral drug discovery, and development company focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV).
Founded in 2011, ReViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors with strong drug like characteristics and good pharmacokinetic properties offering versatility in route of administration. In 2012 ReViral won a significant Seeding Drug Discovery Award from the Wellcome Trust to develop its RSV fusion inhibitors to completion of IND filing. The company also has an RSV replication program at an earlier stage of development and plans to expand its pipeline. In September 2015, ReViral completed a $21 million Series A funding round from a group of leading venture capital investors including Edmond de Rothschild Investment Partners, OrbiMed, and Brace Pharma Capital.
